What is Adicet Bio?
Headquartered in Boston, Massachusetts, Adicet Bio operates at the intersection of advanced immunology and oncology. The company specializes in the design and development of allogeneic immunotherapies, a therapeutic approach that utilizes off-the-shelf cells to treat cancer and other severe conditions. By focusing on the scalability and accessibility of these treatments, Adicet Bio aims to overcome the limitations associated with traditional autologous therapies. Their market position is bolstered by a robust intellectual property portfolio and a commitment to rigorous scientific validation, positioning them as a critical innovator in the next generation of cell-based medicine.
How much funding has Adicet Bio raised?
Adicet Bio has raised a total of $218M across 3 funding rounds:
Series A
$51M
Series B
$80M
Stock Offering
$87M
Series A (2016): $51M with participation from Pontifax, Novartis Venture Fund, and OrbiMed
Series B (2019): $80M led by OrbiMed Partners, OrbiMed Israel, Pontifax, and Novartis Venture Fund
Stock Issuance/Offering (2021): $87M, investors not publicly disclosed
Key Investors in Adicet Bio
Pontifax
Pontifax Venture Capital specializes in groundbreaking innovations in life sciences, focusing on transformative healthcare technologies across all development stages.
Novartis Venture Fund
Novartis is a global pharmaceutical manufacturer headquartered in Switzerland, specializing in developing and producing innovative medications and healthcare solutions.
OrbiMed
OrbiMed Advisors LLC operates as a specialized investment firm focused on the healthcare sector, with deep expertise spanning multiple therapeutic and commercial domains.
What's next for Adicet Bio?
With the recent influx of capital, Adicet Bio is well-positioned to accelerate its clinical development programs and expand its research capabilities. The strategic focus will likely remain on optimizing the manufacturing processes for its allogeneic platforms and advancing lead candidates through human clinical trials. As the company moves deeper into the clinical-stage lifecycle, the emphasis will shift toward demonstrating efficacy and safety profiles that can withstand the scrutiny of regulatory bodies and potential commercial partners. Continued investment in talent acquisition and infrastructure will be paramount as the firm seeks to solidify its leadership in the competitive landscape of immunotherapy.
See full Adicet Bio company page
